Skip to content

Clinical study for the management of Urolithiasis

CliniHajarulayahuda Bhasma in the mancal Evaluation of Shvadamshtradi Kashaya and agement of Mutrashmari (Urolithiasis) - Shvadamshtradi Kashaya, Hajarulayahuda Bhasma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/03/008096
Enrollment
75
Registered
2017-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Urolithiasis

Interventions

Intervention1: Shvadamshtradi Kashaya and Hajarulayahuda Bhasma: Shvadamshtradi Kashaya (Ref: Chakradatta, Asmari Chikitsa â?? 34/28) Dose : 50 ml once a day Dosage form: Decoction Route of Administ

Sponsors

Central Council for Research in Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex with age between 18 and 60 years 2.Patients presenting with or without symptoms of urolithiasis. 3.Radiological evidence of calculi(upto 7 mm) In kidney/ ureter /urinary bladder

Exclusion criteria

Exclusion criteria: 1.Age below 18 years and above 60 years 2.Calculi size more than 7 mm 3.Impacted calculi 4.Gross hydronephrosis, Pyelonephritis, Renal failure 5.Patients having serum creatinine >1.5 mg/dl 6.Patients who cannot report in person every 2 weeks in the OPD 7.Patients with poorly controlled Hypertension ( >160/100 mmHg) 8.Patients with poorly controlled Diabetes Mellitus having Hb A1C of > 7.5% 9.Patients on medication with any other drugs that may have an influence on the outcome of the study. 10.Known case of cardiovascular diseases 11.Known HIV positive cases 12.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study. 13.Alcoholics and/or drug abusers 14.H/o hypersensitivity to any of the trial drugs or their ingredients 15.Pregnant/lactating woman. 16.Patients who have completed participation in any other clinical trial during the past six months. 17.Any other condition which the Investigator thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
Radiological disappearance or reduction of calculi sizeTimepoint: 12 weeks

Secondary

MeasureTime frame
Relief in Signs & Symptoms of MutrashmariTimepoint: 12 weeks

Countries

India

Contacts

Public ContactDr T Maheswar

CCRAS

mahesh_rri@yahoo.co.in9441415266

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 5, 2026